Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 391 | Cloxacillin Sodium 500mg Capsule | J01CF02-520-C10-02-XXX | B | Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci | None | ADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in divided doses every 6 hr. |
| 392 | Cloxacillin Sodium 500mg Injection | J01CF02-520-P40-02-XXX | B | Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci infections | None | ADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours |
| 393 | Clozapine 100 mg Tablet | N05AH02000T1002XX | A | Treatment of resistant schizophrenia | Initial dose : 12.5 mg ( once or twice ) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day | |
| 394 | Clozapine 25 mg Tablet | N05AH02000T1001XX | A | Treatment of resistant schizophrenia | Initial dose : 12.5 mg ( once or twice ) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day | |
| 395 | Coal Tar 20% Solution | D05AA00-000-L52-01-XXX | B | Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis. | None | To dilute 1 cap (15 ml) into 10L of water and soak for 20 minutes. |
| 396 | Coal Tar and Salicylic Acid (various concentrations) Ointment | D05AA00-946-G50-02-XXX | B | Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis | None | Apply to the affected area as required or as in package insert |
| 397 | Colchicine 0.5mg Tablet | M04AC01-000-T10-01-XXX | B | i) Acute gout and prophylaxis of recurrent gout. ii) Leucocytoclastic Vasculitis either cutaneous or systemic involvement, Behcet's syndrome, Urticarial vasculitis, Systemic sclerosis, Sweet's syndrome and severe recalcitrant aphthous stomatitis | None | i) Acute gout: Initial dose, 1 mg, then 0.5 mg after 1 hour. No further tablets should be taken for 12 hours. After 12 hours, treatment can resume if necessary with a maximum dose of 500 micrograms (1 tablet) every 8 hours until symptoms are relieved. The course of treatment should end when symptoms are relieved or when a total of 6 mg (12 tablets) has been taken. No more than 6 mg (12 tablets) should be taken as a course of treatment. After completion of a course, another course should not be started for at least 3 days (72 hours). Prophylaxis of recurrent gout: 0.5 mg bd. ii) 0.5 mg 1-3 times daily depends on disease and severity, up to a maximum of 3 mg/day |
| 398 | Colistimethate Sodium 1 million IU per vial (Polymyxin E) | J01XB01-520-P40-01-XXX | A* | Intravenous administration for the treatment of serious infections caused by Gram negative bacteria, when more commonly used systemic antibacterial agents may be contraindicated or may be ineffective because of bacterial resistance. | None | A minimum of 5 days treatment is generally recommended. For the treatment of respiratory exacerbations in cystic fibrosis patients, treatment should be continued up to 12 days. Children and adults (including elderly): Up to 60kg: 50,000 units/kg/day to a maximum of 75,000 units/kg/day. The total daily dose should be divided into three doses given at approximately 8-hour intervals. Over 60kg: 1-2 million units three times a day. The maximum dose is 6 million units in 24 hours. Renal impairment: In moderate to severe renal impairment, excretion of colistimethate sodium is delayed. Dosage in Renal Impairment (for over 60 kg body weight): - Mild (CrCl 20-50 ml/min): 1-2 million units every 8 hr. - Moderate (CrCl 10-20 ml/min): 1 million units every 12-18 hr. - Severe (CrCl <10 ml/min): 1 million units every 18-24 hr. |
| 399 | Colloidal Bismuth Subcitrate 120 mg Tablet | A02BX05136T1001XX | A | Eradication therapy for Helicobacter Pylori in combination with antibiotics and antisecretory drugs | 240 mg twice daily for 1-2 weeks | |
| 400 | Compound Sodium Lactate (Hartmanns Solution) | B05XA30125P6001XX | C | Replacement of extracellular losses of fluid and electrolytes, as an alkaliniser agent | 100-1000 ml by IV or according to the needs of the patient | |
| 401 | Conjugated estrogens 0.3 mg Tablet | G03CA57-000-T10-03-XXX | A | i. Prevention and management of osteoporosis associated with estrogen deficiency. ii. Female hypoestrogenism. iii. Moderate to severe vasomotor symptoms associated with estrogen deficiency. iv. Atrophic vaginitis and atrophic urethritis. | None | i) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily |
| 402 | Conjugated Estrogens 0.625 mg Tablet | G03CA57-000-T10-01-XXX | A | i. Prevention and management of osteoporosis associated with estrogen deficiency. ii. Female hypoestrogenism. iii. Moderate to severe vasomotor symptoms associated with estrogen deficiency. iv. Atrophic vaginitis and atrophic urethritis. | None | i) 0.3 - 0.625 mg daily ii) 0.3- 1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily |
| 403 | Conjugated Estrogens 0.625mg/g Cream | G03CA57-000-G10-01-XXX | A | Treatment of atrophic vaginitis, dyspareunia and kraurosis vulvae | None | i. Atrophic Vaginitis and Kraurosis Vulvae: Initial dose: Intravaginal 0.5g daily for 21 days and then off for 7 days (cyclical regimen). Dose range: 0.5- 2g daily based on individual response. ii. Dyspareunia: 0.5g intravaginally twice weekly continuous regimen or in a cyclic regimen of 21 days of therapy followed by 7 days off of therapy. |
| 404 | Continuous Ambulatory Peritoneal Dialysis (CAPD) Solution containing 2.3% glucose (Calcium 1.75mmol/L) & (Calcium 1.25mmol/L) | B05DB00908H2504XX | B | For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre | Dose depending on clinical cases | |
| 405 | Continuous Ambulatory Peritoneal Dialysis Solution containing 1.5% Dextrose | B05DB00908H2501XX | B | For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre | Dose depending on clinical cases | |
| 406 | Continuous Ambulatory Peritoneal Dialysis Solution containing 2.5% Dextrose | B05DB00908H2502XX | B | For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre | Dose depending on clinical cases | |
| 407 | Continuous Ambulatory Peritoneal Dialysis Solution containing 4.25% Dextrose | B05DB00908H2503XX | B | For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre | Dose depending on clinical cases | |
| 408 | Copper 375mm2 Intrauterine Device | G02BA02-000-M90-02-XXX | B | Intrauterine contraception. | None | Intrauterine insertion: 1 unit to be replaced within 5 years from the date of insertion. |
| 409 | Copper Sulphate Crystal | D08A000183F9901XX | C | Wounds | The tip of the crystal should be moistened by dipping in water and applied carefully to the lesion | |
| 410 | Corifollitropin Alfa 100mcg/0.5ml solution for injection | G03GA09-000-P50-01-XXX | A* | Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program | None | Women with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information |
| 411 | Corifollitropin Alfa 150mcg/0.5ml solution for injection | G03GA09-000-P50-02-XXX | A* | Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program | None | Women with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information |
| 412 | Crotamiton 10 % Cream | P03A000000G1001XX | B | i) Pruritus ii) Scabies iii) Insect bite reactions | i) and iii) Massage into affected area until the medication is completely absorbed. Repeat as needed. Apply 2 or 3 times daily ii) Apply to the whole body from below the chin. 2nd application is applied 24 hr later. May need to use once daily for up to 5 days. | |
| 413 | Cyanocobalamin 0.1 mg Injection | B03BA01000P3001XX | B | i) Prophylaxis of anaemia ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption | i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). Maintenance: 100 mcg monthly to sustain remission OR AS PRESCRIBED. | |
| 414 | Cyanocobalamin 1 mg Injection | B03BA01000P3002XX | B | i) Prophylaxis of anaemia associated with Vitamin B12 deficiency ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption | i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). OR AS PRESCRIBED. | |
| 415 | Cyanocobalamin 50 mcg Tablet | B03BA01000T1002XX | B | Vitamin B12 deficiency of dietary origin | ADULT 50-150 mcg daily. CHILD 50-105 mcg daily in 1-3 divided doses | |
| 416 | Cyclopentolate 0.2% with Phenylephrine 1% Eye Drops | S01GA55-990-D20-01-XXX | A | Dilating agent for premature babies | None | 1 drop every 5 - 10 minutes; not exceeding three times to produce rapid mydriasis. Observe infants closely for at least 30 minutes |
| 417 | Cyclopentolate 1% Eye Drops | S01FA04-000-D20-02-XXX | A/KK | Mydriasis and cycloplegia | None | ADULT : 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. CHILD : 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. Pre-treatment on the day prior to examination is usually not necessary. If desirable, 1 or 2 drops may be instilled the evening prior to examination. |
| 418 | Cyclophosphamide 1 g Injection | L01AA01000P4002XX | A | i) Solid tumours ii) Leukaemia, non-Hodgkin's lymphoma, multiple myeloma iii) Severe lupus nephritis (Class III and IV) iv) Other systemic vasculitis v) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis vi) Pemphigus vulgaris. | For all indications: a. for continuous treatment in adults and children: 3 to 6 mg/kg body weight daily (equivalent to 120 to 240 mg/m² body surface) b. for intermittent treatment: 10 to 15 mg/kg body weight (equivalent to 400 to 600 mg/m² body surface) at intervals of 2 to 5 days c. for high-dose intermittent treatment: e.g. 20 to 40 mg/kg body weight (equivalent to 800 to 1600 mg/m² body surface) and higher doses (e.g. for conditioning prior to bone-marrow transplantation) at intervals of 21 to 28 days. Dosing is individualised and according to product insert/protocol. | |
| 419 | Cyclophosphamide 200 mg Injection | L01AA01000P4001XX | A | i) Solid tumours ii) Leukaemia, non-Hodgkin's lymphoma, multiple myeloma iii) Severe lupus nephritis (Class III and IV) iv) Other systemic vasculitis v) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis vi) Pemphigus vulgaris. | For all indications: a. for continuous treatment in adults and children: 3 to 6 mg/kg body weight daily (equivalent to 120 to 240 mg/m² body surface) b. for intermittent treatment: 10 to 15 mg/kg body weight (equivalent to 400 to 600 mg/m² body surface) at intervals of 2 to 5 days c. for high-dose intermittent treatment: e.g. 20 to 40 mg/kg body weight (equivalent to 800 to 1600 mg/m² body surface) and higher doses (e.g. for conditioning prior to bone-marrow transplantation) at intervals of 21 to 28 days. Dosing is individualised and according to product insert/protocol. | |
| 420 | Cyclophosphamide 50 mg Tablet | L01AA01000T1001XX | A | i) Solid tumours ii) Leukaemia, lymphoma, autoimmune disorders, autoimmune bullous diseases, connective tissue disease, pyoderma gangrenosum iii) Severe lupus nephritis (Class III & IV) iv) Systemic vasculitis and steroid resistant/dependent nephrotic syndrome, polyarteritis nodosa, wegener granulomatosis v) Systemic lupus erythematosus (SLE), rheumatoid arthritis | i) & ii) ADULT: 50 - 100 mg/day. Monitor full blood count (FBC), liver function, urine microscopy and renal function. CHILD, up to 1 year: 10 - 20 mg daily, 1 - 5 years: 30 - 50 mg daily, 6 - 12 years: 50 - 100 mg daily iii) 2 mg/kg/day for 3 - 4 months iv) 2 mg/kg/day for 3 - 6 months v) 1 - 1.5 mg/kg/day orally in divided doses Dosing is individualised and according to product insert/protocol. |